RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
RxSight, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.69+0.18 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $194.59M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
76.6%+65.0 pts over 5 years
Operating margin
-35.8%+205.4 pts over 5 years
Net margin
-29.0%−216.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.9% | +40.0% | +55.7% | – | |
| Gross profit | +4.1% | +69.0% | +127.1% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -14.0% | |
| Return on assets | – | – | -12.4% | |
| Current ratio | – | 7.03 | 10.95 | |
| Interest coverage | – | -69.4× | -2536.4× | |
| Inventory turnover | – | – | 1.2× | |
| Capex to revenue | – | 17.3% | 2.8% | |
| Diluted shares | – | 6M | 41M |
Where the cash went
Fiscal 2021 to 2025, five years combined
RxSight generated $177.61M from operations and spent $18.42M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$177.61M
Used
$18.42M
Capital expenditure$18.42M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-29.0%
×Asset turnover0.43×
×Equity multiplier1.13×
=Return on equity, FY2025-14.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -29.0% | 0.43× | 1.13× | -14.0% |
| FY2024 | -19.6% | 0.56× | 1.13× | -12.4% |
| FY2023 | -54.6% | 0.54× | 1.33× | -38.8% |
| FY2022 | -136.2% | 0.29× | 1.50× | -58.5% |
| FY2021 | -215.5% | 0.15× | -1.00× | 33.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$38.94M
- Cash generatingOperating cash flow above zero-$15.51M
- Return on assets improvedROA up on the prior year-15.0% → -12.2%
- Earnings backed by cashOperating cash flow above net income-$15.51M vs -$38.94M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.36 → 10.95
- No dilutionShare count did not rise39M → 41M
- Gross margin improvedGross margin up on the prior year70.71% → 76.60%
- More efficientAsset turnover rose0.77 → 0.42